Skip to content
type1.science
Phase 2Active, not recruitingNCT05743244

JAKPOT T1D: Abrocitinib and ritlecitinib in new-onset T1D

TrialNet/NIDDK phase-2 trial comparing two selective oral JAK-pathway drugs - abrocitinib and ritlecitinib - with placebo for preservation of C-peptide in newly diagnosed T1D.

Primary endpoints

  • C-peptide preservation in new-onset T1D

Results so far

No results posted as of the May 2026 registry update reviewed here.

The full picture

JAKPOT is the TrialNet companion to the baricitinib story: a test of whether more selective oral JAK-pathway drugs can reproduce C-peptide preservation with an acceptable safety profile.